Patients in DAS28 remission (n=1931) fulfilling or not fulfilling each of the two new criteria
| Boolean based | SDAI based | |||||
|---|---|---|---|---|---|---|
| Yes | No | p Value | Yes | No | p Value | |
| Number of cases | 406 | 1525 | 649 | 1282 | ||
| % of DAS28 remission cases | 21.0 | 79.0 | 33.6 | 66.4 | ||
| Age, in years (mean±SD) | 56.4±14.3 | 60.6±13.5 | <0.001 | 57.7±14.1 | 60.8±13.4 | <0.001 |
| Female (%) | 72.4 | 66.4 | 0.023 | 69.2 | 66.9 | 0.328 |
| Disease duration, in years (mean±SD) | 7.7±7.6 | 10.4±9.2 | <0.001 | 8.2±7.9 | 10.7±9.3 | |
| % with disease duration ≤2 years | 20.6 | 15.4 | <0.001 | 19.4 | 15.0 | <0.001 |
| Physician global* (mean±SD) | 0.6±1.0 | 1.4±1.4 | <0.001 | 0.3±0.5 | 1.6±1.5 | <0.001 |
| 0–3 | 98.0 | 91.7 | <0.001 | 100.0 | 89.5 | <0.001 |
| 7–10 | 0.7 | 0.8 | ||||
| Swollen joint count (mean±SD) | 0.1±0.2 | 0.2±0.8 | <0.001 | 0.0±0.2 | 0.3±0.9 | <0.001 |
| Swollen joint count, grouped (%) | ||||||
| 0 | 94.1 | 87.0 | <0.001 | 96.8 | 84.3 | <0.001 |
| 1 | 5.9 | 6.8 | 3.1 | 8.3 | ||
| >1 | 6.3 | 0.2 | 7.3 | |||
| Tender joint count (mean±SD) | 0.1±0.2 | 0.2±0.6 | <0.001 | 0.0±0.2 | 0.2±0.7 | <0.001 |
| Tender joint count, grouped (%) | ||||||
| 0 | 94.3 | 88.7 | <0.001 | 96.5 | 86.6 | <0.001 |
| 1 | 5.7 | 6.6 | 3.1 | 8.1 | ||
| >1 | 4.8 | 0.5 | 5.4 | |||
| Swollen or tender joints>1 (%) | 0.0 | 10.4 | <0.001 | 0.6 | 12.0 | <0.001 |
| CRP>1 (%) | 0.0 | 11.5 | <0.001 | 3.7 | 11.8 | <0.001 |
| in mg/dl (mean±SD) | 0.3±0.2 | 0.6±2.2 | <0.001 | 0.3±0.3 | 0.7±2.4 | <0.001 |
| Swollen or tender joints or CRP>1 (%) | 0.0 | 21.0 | <0.001 | 4.3 | 22.8 | <0.001 |
| ESR in mm/h (mean±SD) | 12.5±7.7 | 9.5±5.9 | <0.001 | 11.9±7.4 | 9.2±5.6 | <0.001 |
| DAS28 (mean±SD) | 1.8±0.5 | 2.0±0.4 | <0.001 | 1.8±0.5 | 2.1±0.4 | <0.001 |
| Rheumatoid factor positive (%) | 61.9 | 66.8 | 0.085 | 60.3 | 68.6 | 0.001 |
| Pain* (mean±SD) | 0.9±1.2 | 3.2±2.0 | <0.001 | 1.3±1.3 | 3.5±2.0 | <0.001 |
| 0 | 44.8 | 6.7 | <0.001 | 34.4 | 4.8 | <0.001 |
| 1 | 37.7 | 11.1 | 30.2 | 9.9 | ||
| >1 | 17.4 | 82.2 | 35.4 | 85.4 | ||
| Fatigue* (mean±SD) | 1.0±1.6 | 3.0±2.5 | <0.001 | 1.3±1.7 | 3.3±2.5 | <0.001 |
| 0 | 52.6 | 19.9 | <0.001 | 45.7 | 17.3 | <0.001 |
| 1 | 23.6 | 11.7 | 18.9 | 11.8 | ||
| >1 | 23.8 | 68.4 | 35.4 | 70.9 | ||
| Patient global* (mean±SD) | 0.6±0.5 | 3.5±1.6 | <0.001 | 1.2±1.0 | 3.7±1.6 | <0.001 |
| 0 | 42.4 | 1.6 | <0.001 | 27.9 | 1.2 | <0.001 |
| 1 | 57.6 | 2.4 | 34.2 | 3.8 | ||
| >1 | 0 | 96.0 | 37.9 | 94.9 | ||
| FFbH† (mean±SD) | 93.4±12.4 | 81.9±18.2 | <0.001 | 92.4±12.0 | 80.2±18.8 | <0.001 |
| HAQ (mean±SD) | 0.6±0.4 | 0.9±0.51 | 0.6±0.34 | 0.9±0.53 | ||
| Morning stiffness >30 min (%) | 2.5 | 16.1 | <0.001 | 3.1 | 18.2 | <0.001 |
| Comorbidity, any (%) | 54.1 | 69.7 | <0.001 | 55.5 | 72.1 | <0.001 |
| Coronary heart disease (%) | 7.8 | 8.4 | 0.832 | 6.6 | 9.1 | 0.07 |
| Osteoporosis (%) | 11.3 | 17.9 | 0.002 | 10.4 | 19.7 | <0.001 |
| Osteoarthritis (%) | 5.1 | 13.5 | <0.001 | 7.1 | 14.1 | <0.001 |
| Degenerative spine disease (%) | 4.3 | 14.7 | <0.001 | 6.3 | 15.7 | <0.001 |
*Numerical rating scale from 0–10, 0 indicating best, 10 worst status.
†Score range from 0-100, 100 indicating unlimited functional ability.
CRP, C-reactive protein; DAS28, 28-joint count Disease Activity Score; ESR, erythrocyte sedimentation rate; FFbH, Hannover Functional Status Questionnaire; HAQ, Health Assessment Questionnaire.